LumiThera develops treatment solutions utilizing Photobiomodulation to improve visual function, stop or slow the progression of debilitating eye diseases and prevent vision loss and blindness.
LumiThera’s first product, the Valeda Light Delivery System, is the first approved treatment for Dry Age-Related Macular Degeneration using Photobiomodulation.
The Valeda Light Delivery System is CE Marked in Europe. Valeda is in clinical trials and not approved for use in the United States.
Experimentica Ltd. is a global contract research organization developing and offering novel preclinical Ophthalmology models and services to sponsors from Pharma, Biotech, and Academia.
We offer an industry-leading portfolio of in vitro, ex vivo and in vivo models in rodents and larger animals, as well as custom models, GLP-like and GLP Tolerability and Toxicity ocular studies.
The company is headquartered in Kuopio, Finland, with R&D sites in Finland, Lithuania, and the United States.
Edison is the world leader in investor relations. Having established the paid research sector we are now re-making it as Investor Relations 3.0.
Why? Because many complex trends have led to a simple disconnect between listed companies and investors. It is our mission to overcome these completely and ensure investors are fully aware of the investment opportunity our clients offer.
To do so we write award-winning research, distribute it across the global investment community, use analytics to spot investor interest and then set-up meetings to discuss the investment case in detail.
As a result our clients see more demand for their stock which enables them to deliver more of their other financial objectives.